Have Aclarion insiders bought shares recently?

Yes. Insiders of Aclarion (ACON) filed 6 open-market purchases in the last 90 days; the latest was filed on Aug 19, 2026.

How often do Aclarion insiders buy and sell shares?

Since 2022, Aclarion insiders reported 21 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2026.

Who is selling Aclarion stock?

No open-market sale by an insider of Aclarion (ACON) was filed with the SEC in the last 90 days.

Do members of Congress trade ACON?

No trade in Aclarion (ACON) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Aclarion (ACON) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at ACON buy and sell in the last 90 days?Which members of Congress and which funds traded ACON recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

ACON price and disclosed activity

−74.6% (−$4.59) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Show the 11 trades in this range as a list

Amanda M Williams, Director · Insider purchase, about $16Ktraded Aug 17, 2026, filed Aug 19, 2026
Gregory A Gould, CFO · Insider purchase, about $25Ktraded Aug 14, 2026, filed Aug 18, 2026
Ryan Bond, Director · Insider purchase, about $50Ktraded Aug 13, 2026, filed Aug 17, 2026
David K Neal, Director · Insider purchase, about $18Ktraded Aug 13, 2026, filed Aug 17, 2026
Brent Ness, Chief Executive Officer · Insider purchase, about $12Ktraded Aug 13, 2026, filed Aug 17, 2026
William Wesemann, Director · Insider purchase, about $5Ktraded Aug 13, 2026, filed Aug 17, 2026
Scott Breidbart, Director · Insider purchase, about $18Ktraded May 12, 2026, filed May 12, 2026
Brent Ness, Chief Executive Officer · Insider purchase, about $20Ktraded May 11, 2026, filed May 11, 2026
David K Neal, Director · Insider purchase, about $7.8Ktraded May 11, 2026, filed May 12, 2026
William Wesemann, Director · Insider purchase, about $5.2Ktraded May 6, 2026, filed May 8, 2026
Brent Ness, Chief Executive Officer · Insider purchase, about $62traded Nov 26, 2025, filed Dec 1, 2025

Insider open-market trades, filed in the last 90 days6 buys · 0 sales~$126K boughtInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, last 12 monthsNoneNo followed fund reported a changeFund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Services-Medical Laboratories company based in Broomfield, Co.

Last 12 months

−74.6%

S&P 500 +12.3% over the same dates

Market value

$4.5M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 21K shares sold short (0.7% of shares outstanding), −12.8% vs the previous count, 1.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

Latest results: quarter ending Sep 30, 2026

Revenue

$34K

+78.1% vs the same quarter a year earlier

Free cash flow, last 12 months

−$2.02M

This quarter −$2.02M, a year earlier −$1.17M

Net debt

—

Debt —, cash $14.2M, at Sep 30, 2026

Net income, last 12 months

−$10.1M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Feb 21, 2024.

Insider buying and selling since 2022

Insiders of Aclarion reported 21 open-market purchases and 0 sales since 2022; purchases in 4 different years, most recently 2026.

Year	Bought	Sold
2026	$177K10×10 trades	—
2025	$621×1 trade	—
2023	$1K1×1 trade	—
2022	$278K9×9 trades	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

Company size

10-K filed Mar 18, 2026

Revenue, fiscal 2025

$76K

+65.6% vs the year before

Net income, fiscal 2025

−$7.23M

A loss for the year

Shares outstanding

2.88M

As of Nov 3, 2026

Latest

See everything

Insider buying

Amanda M WilliamsDirector

Filed 3mo ago

Bought

~$16K5,857 sh @ $2.73

6 insiders in a week, a first since 2022Traded Aug 17 · filed 2 days later

Since the trade −43.7% · S&P 500 −2.4% · to Nov 13

Want the short version?

Aclarion

How this filing works

Questions about Aclarion insider trading

Insiders who traded Aclarion

Other Services-Medical Laboratories companies

ACON price and disclosed activity

Latest results: quarter ending Sep 30, 2026

Insider buying and selling since 2022

Company size

Latest

~$16K5,857 sh @ $2.73

~$25K10K sh @ $2.45

~$50K21K sh @ $2.37

~$18K7,500 sh @ $2.40

~$12K5,234 sh @ $2.31

Insider buying and selling since 2022